SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 |
SCHEDULE 13G
|
UNDER THE SECURITIES EXCHANGE ACT OF 1934
|
(Amendment No. 1)*
|
Zentalis Pharmaceuticals, Inc. (Name of Issuer) |
Common Stock, $0.001 par value per share (Title of Class of Securities) |
98943L107 (CUSIP Number) |
01/08/2025 (Date of Event Which Requires Filing of this Statement) |
Check the appropriate box to designate the rule pursuant to which this Schedule is filed: |
Rule 13d-1(b) |
Rule 13d-1(c) |
Rule 13d-1(d) |
SCHEDULE 13G
|
CUSIP No. | 98943L107 |
1 | Names of Reporting Persons
Walters William T | ||||||||
2 | Check the appropriate box if a member of a Group (see instructions)
(a)
(b) | ||||||||
3 | Sec Use Only | ||||||||
4 | Citizenship or Place of Organization
UNITED STATES
| ||||||||
Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
9 | Aggregate Amount Beneficially Owned by Each Reporting Person
5,000,000.00 | ||||||||
10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
| ||||||||
11 | Percent of class represented by amount in row (9)
7.0 % | ||||||||
12 | Type of Reporting Person (See Instructions)
IN |
SCHEDULE 13G
|
CUSIP No. | 98943L107 |
1 | Names of Reporting Persons
WALTERS GROUP | ||||||||
2 | Check the appropriate box if a member of a Group (see instructions)
(a)
(b) | ||||||||
3 | Sec Use Only | ||||||||
4 | Citizenship or Place of Organization
NEVADA
| ||||||||
Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
9 | Aggregate Amount Beneficially Owned by Each Reporting Person
5,000,000.00 | ||||||||
10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
| ||||||||
11 | Percent of class represented by amount in row (9)
7.0 % | ||||||||
12 | Type of Reporting Person (See Instructions)
PN |
SCHEDULE 13G
|
CUSIP No. | 98943L107 |
1 | Names of Reporting Persons
Walters, Susan B. | ||||||||
2 | Check the appropriate box if a member of a Group (see instructions)
(a)
(b) | ||||||||
3 | Sec Use Only | ||||||||
4 | Citizenship or Place of Organization
UNITED STATES
| ||||||||
Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
9 | Aggregate Amount Beneficially Owned by Each Reporting Person
5,000,000.00 | ||||||||
10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
| ||||||||
11 | Percent of class represented by amount in row (9)
7.0 % | ||||||||
12 | Type of Reporting Person (See Instructions)
IN |
SCHEDULE 13G
|
Item 1. | |
(a) | Name of issuer:
Zentalis Pharmaceuticals, Inc. |
(b) | Address of issuer's principal executive offices:
10275 SCIENCE CENTER DRIVE, 10275 SCIENCE CENTER DRIVE, SAN DIEGO, CALIFORNIA, 92121. |
Item 2. | |
(a) | Name of person filing:
This Schedule 13G ("Schedule") is being filed by William T. Walters, The Walters Group (the "TWG") and Susan B. Walters (together, the "Reporting Persons").
TWG directly owns the shares of common stock reported in this Schedule (the "Shares"). William T. Walters may be deemed to share voting and dispositive power with respect to the Shares. Susan B. Walters is the general partner and majority member of TWG and may be deemed to share voting and dispositive power with respect to the Shares.
Each Reporting Person disclaims beneficial ownership with respect to any Shares other than the Shares owned directly by such Reporting Person (if any). |
(b) | Address or principal business office or, if none, residence:
The address of each Reporting Person is 8975 S. Pecos Road, Unit 6A, Henderson, Nevada 89074. |
(c) | Citizenship:
TWG was organized as a Nevada general partnership. William T. Walters and Susan B. Walters are U.S. citizens. |
(d) | Title of class of securities:
Common Stock, $0.001 par value per share |
(e) | CUSIP No.:
98943L107 |
Item 4. | Ownership |
(a) | Amount beneficially owned:
Each of William T. Walters, TWG and Susan B. Walters may be deemed to beneficially own 5,000,000 Shares. |
(b) | Percent of class:
7.0 %
|
(c) | Number of shares as to which the person has:
|
(i) Sole power to vote or to direct the vote:
0 | |
(ii) Shared power to vote or to direct the vote:
5,000,000 | |
(iii) Sole power to dispose or to direct the disposition of:
0 | |
(iv) Shared power to dispose or to direct the disposition of:
5,000,000 | |
Item 5. | Ownership of 5 Percent or Less of a Class. |
Item 6. | Ownership of more than 5 Percent on Behalf of Another Person. |
Not Applicable
| |
Item 7. | Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person. |
Not Applicable
| |
Item 8. | Identification and Classification of Members of the Group. |
Not Applicable
| |
Item 9. | Notice of Dissolution of Group. |
Not Applicable
|
Item 10. | Certifications: |
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
|
SIGNATURE | |
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|
|
|
|
|
|
|